|
|||||||||||||||
|
UBBFriend: Email This Page to Someone! |
HUM-MOLGEN
Biotechnical requests and sources Discover the Next IDE Inhibitor with the Newly Launched SensoLyteŽ IDE Activity Assay
|
next newest topic | next oldest topic |
Author | Topic: Discover the Next IDE Inhibitor with the Newly Launched SensoLyteŽ IDE Activity Assay |
anaspec Member |
posted 06-11-2014 01:03 AM
Discover your next Insulin Degrading Enzyme (IDE) inhibitor by using the newly launched SensoLyteŽ 520 IDE activity assay from AnaSpec. This is the first FRET-based (Ex/Em=490/520 nm) IDE assay that is commercially available and can be used for high-throughput screening (HTS) of IDE inhibitor lead compounds. The highly sensitive substrate used in the assay can detect as low as 0.8 ng/ml active IDE and has minimal cross reaction with Neprilysin, TACE, -Secretase, ADAM10 and BACE2. Insulin degrading enzyme (IDE), an extremely conserved Zn2+ metalloendopeptidase, belongs to the M16A metallopeptidase family (1-3). IDE is expressed in almost all tissues and distributed in the cytosol. It degrades various substrates such as insulin, IGF-II, TGF-α, glucagon, amylin, calcitonin, β-amyloid and amyloid precursor protein (APP) (4-6). Growing evidence has indicated that IDE may be involved in the pathogenesis of Alzheimer's disease and diabetes mellitus type 2 (2, 7, 8). For more information, please visit: https://www.anaspec.com/products/promotions.asp?id=125&col=2&row=1 References AnaSpec, EGT Group
IP: 12.169.96.11 |
All times are ET (US) | next newest topic | next oldest topic |
Copyright by HUM-MOLGEN 1995-2017
Powered by: Ultimate Bulletin Board, Version 5.44a
© Infopop Corporation (formerly Madrona Park, Inc.), 1998 - 2000.